prednisolone sodium phosphate 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
prednisone and prednisolone derivatives 4451 125-02-0

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • prednisolone sodium phosphate
  • sodium prednisolone phosphate
  • prednisolone phosphoric acid
  • prednisolone phosphate
  • Molecular weight: 440.43
  • Formula: C21H29O8P
  • CLOGP: -0.05
  • LIPINSKI: 0
  • HAC: 8
  • HDO: 4
  • TPSA: 141.36
  • ALOGS: -3.01
  • ROTB: 4
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

PropertyValueReference
BA (Bioavailability) 82 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
S (Water solubility) 0.22 mg/mL Bocci G, Oprea TI, Benet LZ

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
kinase-safety-class ACVR2A,ACVR2B,ACVRL1,AKT2,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,DDR1,DYRK1B,EGFR,EIF2AK3,EPHB4,ERBB2,GRK2,GSK3B,ITK,JAK2,JAK3,KDR,MAP2K6,MAP3K14,MAP3K21,MAP3K7,MAPK10,MAPK7,MAPK9,MAPKAPK2,MTOR,NTRK2,PDK1,PDK2,PDK4,PIK3CB,PIK3CG,PIM2,PLK1,PRKDC,SIK2,STK33,SYK,TEK,TGFBR1,TTK,ZAP70 50
kinase-selectivity-class AXL,BRAF,CDK4,CDK9,EPHB4,ERBB2,GRK2,MAP2K6,MAP3K14,PIK3CD,SYK,TEK,TGFBR1,ZAP70 14
mdck-mdr1-bcrp-efflux MDCK-MDR1-BCRP efflux ratio 0.287 Moderate 0.77
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pld-class Phospholipidosis risk class (1 = positive, 0 = negative) 0 Moderate 0.77
rat-kpuu-brain Rat brain Kpuu 0.002 % Moderate 0.77

Approvals:

DateAgencyCompanyOrphan
Dec. 19, 1973 FDA NOVARTIS

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hepatitis B reactivation 269.99 23.18 64 7914 3910 90616559
Acute hepatic failure 129.83 23.18 55 7923 22506 90597963
Asthma 105.83 23.18 118 7860 242042 90378427
Neurologic neglect syndrome 102.86 23.18 36 7942 8811 90611658
Carotid artery thrombosis 98.11 23.18 35 7943 9057 90611412
Adjustment disorder 96.10 23.18 35 7943 9607 90610862
Personality disorder 90.90 23.18 36 7942 12408 90608061
Gangrene 89.71 23.18 36 7942 12840 90607629
Temperature regulation disorder 88.74 23.18 37 7941 14542 90605927
Bedridden 88.23 23.18 35 7943 12113 90608356
Arterial occlusive disease 87.41 23.18 35 7943 12411 90608058
Hemiplegia 85.07 23.18 37 7941 16123 90604346
Foetal death 82.35 23.18 39 7939 20684 90599785
Angina pectoris 81.99 23.18 48 7930 39112 90581357
Sensory loss 77.95 23.18 36 7942 18039 90602430
Motor dysfunction 75.82 23.18 36 7942 19194 90601275
Affect lability 74.87 23.18 35 7943 18028 90602441
Coordination abnormal 72.24 23.18 36 7942 21320 90599149
Skin haemorrhage 72.20 23.18 36 7942 21344 90599125
Food allergy 71.86 23.18 38 7940 25440 90595029
Psoriasis 69.65 23.18 75 7903 147679 90472790
Hemiparesis 66.59 23.18 39 7939 31780 90588689
Foot fracture 64.78 23.18 36 7942 26570 90593899
Rhinorrhoea 64.48 23.18 57 7921 88259 90532210
Sinus congestion 63.76 23.18 36 7942 27388 90593081
Respiratory tract congestion 61.09 23.18 35 7943 27375 90593094
Sneezing 60.90 23.18 36 7942 29833 90590636
Muscle spasticity 60.31 23.18 38 7940 35284 90585185
Eating disorder 57.67 23.18 34 7944 28039 90592430
Sinus disorder 56.17 23.18 36 7942 34411 90586058
Immunodeficiency 55.64 23.18 39 7939 43195 90577274
Coeliac disease 54.54 23.18 39 7939 44571 90575898
Wheezing 52.44 23.18 83 7895 237997 90382472
Lower limb fracture 50.67 23.18 49 7929 84964 90535505
Heart sounds 50.30 23.18 13 7965 1131 90619338
Prolonged expiration 49.08 23.18 13 7965 1244 90619225
Aphasia 46.83 23.18 35 7943 42777 90577692
Upper respiratory tract infection 46.69 23.18 57 7921 128261 90492208
Immobile 44.94 23.18 18 7960 6380 90614089
Hyponatraemic seizure 44.11 23.18 10 7968 500 90619969
Oedema 41.58 23.18 68 7910 200227 90420242
Dysarthria 41.42 23.18 36 7942 54446 90566023
Enterococcal sepsis 41.37 23.18 12 7966 1604 90618865
Keratopathy 40.85 23.18 10 7968 698 90619771
Cataract 40.06 23.18 40 7938 72052 90548417
Influenza 39.93 23.18 55 7923 139209 90481260
Prescribed overdose 39.85 23.18 46 7932 97579 90522890
Treatment failure 39.07 23.18 84 7894 303844 90316625
Rash erythematous 37.80 23.18 37 7941 65067 90555402
Chest discomfort 37.22 23.18 53 7925 138312 90482157
Skin exfoliation 36.48 23.18 37 7941 67876 90552593
Tonsillar disorder 35.60 23.18 10 7968 1192 90619277
Cystitis 35.20 23.18 36 7942 66682 90553787
Fluid retention 35.10 23.18 41 7937 88050 90532419
Nasal oedema 34.40 23.18 15 7963 6569 90613900
Osteoporosis 33.68 23.18 42 7936 96489 90523980
Loss of personal independence in daily activities 33.51 23.18 50 7928 136055 90484414
Pyrexia 32.26 23.18 129 7849 660356 89960113
Respiration abnormal 31.66 23.18 15 7963 7948 90612521
Drug hypersensitivity 31.56 23.18 101 7877 463508 90156961
Meningitis cryptococcal 31.44 23.18 10 7968 1823 90618646
Influenza like illness 31.25 23.18 37 7941 80574 90539895
Depressive symptom 30.77 23.18 13 7965 5272 90615197
Rheumatoid arthritis 28.40 23.18 83 7895 362531 90257938
Respiratory tract infection 27.81 23.18 30 7948 59048 90561421
Bursitis 27.71 23.18 45 7933 131609 90488860
Oesophageal disorder 27.59 23.18 10 7968 2703 90617766
Appetite disorder 26.82 23.18 14 7964 9119 90611350
Intentional product misuse 26.59 23.18 36 7942 89568 90530901
Cough 26.58 23.18 82 7896 368880 90251589
Fracture 26.28 23.18 19 7959 22057 90598412
Vomiting 25.87 23.18 137 7841 788156 89832313
Hyperhidrosis 25.24 23.18 44 7934 136261 90484208
Osteonecrosis 23.36 23.18 19 7959 26222 90594247

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Choroiditis 262.74 28.76 48 2276 1327 42617684
Intraocular pressure increased 208.87 28.76 52 2272 6381 42612630
Endophthalmitis 196.13 28.76 46 2278 4387 42614624
Uveitis 176.21 28.76 49 2275 9209 42609802
Visual acuity reduced 153.27 28.76 51 2273 17499 42601512
Eye pain 146.76 28.76 49 2275 16981 42602030
Hypersensitivity 73.79 28.76 47 2277 72323 42546688
Condition aggravated 73.37 28.76 80 2244 260674 42358337
Cardiac disorder 57.98 28.76 35 2289 48897 42570114
Total lung capacity abnormal 35.10 28.76 12 2312 4431 42614580
Product use issue 33.42 28.76 30 2294 76721 42542290
Spirometry abnormal 33.38 28.76 12 2312 5134 42613877
Meningomyelitis herpes 33.33 28.76 5 2319 38 42618973
Pulmonary vasculitis 31.08 28.76 12 2312 6254 42612757
Hepatitis B reactivation 30.92 28.76 11 2313 4567 42614444
Steroid dependence 30.26 28.76 12 2312 6710 42612301
Nocardiosis 29.57 28.76 11 2313 5179 42613832

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Choroiditis 224.50 20.76 47 9982 1568 110577702
Intraocular pressure increased 159.28 20.76 53 9976 10823 110568447
Endophthalmitis 144.66 20.76 46 9983 8141 110571129
Asthma 111.48 20.76 125 9904 250166 110329104
Uveitis 110.58 20.76 49 9980 21661 110557609
Visual acuity reduced 106.63 20.76 54 9975 32119 110547151
Neurologic neglect syndrome 100.05 20.76 36 9993 9262 110570008
Carotid artery thrombosis 95.08 20.76 35 9994 9603 110569667
Adjustment disorder 91.22 20.76 35 9994 10760 110568510
Temperature regulation disorder 88.79 20.76 36 9993 12790 110566480
Personality disorder 88.76 20.76 36 9993 12801 110566469
Foetal death 84.25 20.76 37 9992 16008 110563262
Gangrene 80.39 20.76 36 9993 16305 110562965
Arterial occlusive disease 79.40 20.76 35 9994 15273 110563997
Eye pain 76.98 20.76 51 9978 50048 110529222
Food allergy 76.54 20.76 37 9992 19911 110559359
Chorioretinopathy 76.13 20.76 21 10008 2274 110576996
Affect lability 72.81 20.76 35 9994 18602 110560668
Hemiplegia 71.88 20.76 37 9992 22745 110556525
Sensory loss 71.05 20.76 36 9993 21421 110557849
Angina pectoris 69.18 20.76 52 9977 62243 110517027
Coordination abnormal 68.33 20.76 37 9992 25191 110554079
Psoriasis 67.57 20.76 73 9956 139920 110439350
Motor dysfunction 66.68 20.76 36 9993 24370 110554900
Skin haemorrhage 66.10 20.76 36 9993 24791 110554479
Wheezing 61.14 20.76 94 9935 255136 110324134
Bedridden 61.05 20.76 28 10001 13397 110565873
Immunodeficiency 60.78 20.76 40 9989 38798 110540472
Sinus congestion 59.25 20.76 36 9993 30423 110548847
Muscle spasticity 58.68 20.76 38 9991 35877 110543393
Sneezing 57.63 20.76 36 9993 31948 110547322
Sinus disorder 56.87 20.76 36 9993 32692 110546578
Respiratory tract congestion 56.27 20.76 35 9994 30822 110548448
Rhinorrhoea 55.70 20.76 57 9972 102609 110476661
Hepatitis B reactivation 55.23 20.76 22 10007 7462 110571808
Hemiparesis 54.04 20.76 39 9990 43864 110535406
Eating disorder 53.76 20.76 34 9995 30824 110548446
Coeliac disease 52.33 20.76 38 9991 43149 110536121
Heart sounds 49.92 20.76 13 10016 1130 110578140
Skin exfoliation 46.34 20.76 48 9981 87603 110491667
Prolonged expiration 45.98 20.76 13 10016 1539 110577731
Foot fracture 44.13 20.76 28 10001 25518 110553752
Upper respiratory tract infection 42.70 20.76 56 9973 131272 110447998
Aphasia 41.90 20.76 38 9991 58959 110520311
Prescribed overdose 41.06 20.76 45 9984 87536 110491734
Product use issue 40.38 20.76 88 9941 311607 110267663
Oedema 40.30 20.76 70 9959 209906 110369364
Hyponatraemic seizure 40.13 20.76 10 10019 729 110578541
Lower limb fracture 39.36 20.76 41 9988 75307 110503963
Osteonecrosis 39.31 20.76 29 10000 33712 110545558
Keratopathy 38.42 20.76 11 10018 1362 110577908
Cataract 37.54 20.76 41 9988 79444 110499826
Rheumatoid arthritis 37.01 20.76 83 9946 299530 110279740
Loss of personal independence in daily activities 35.52 20.76 55 9974 149965 110429305
Cystitis 34.61 20.76 36 9993 66000 110513270
Respiration abnormal 34.06 20.76 17 10012 9792 110569478
Nasal oedema 33.42 20.76 15 10014 6824 110572446
Hypersensitivity 33.29 20.76 96 9933 403902 110175368
Tonsillar disorder 33.19 20.76 10 10019 1479 110577791
Enterococcal sepsis 32.56 20.76 12 10017 3300 110575970
Acute kidney injury 32.03 20.76 9 10020 635421 109943849
Arthritis 31.02 20.76 55 9974 167531 110411739
Influenza 30.66 20.76 55 9974 169046 110410224
Fluid retention 30.31 20.76 40 9989 94267 110485003
Chest discomfort 29.57 20.76 55 9974 173793 110405477
Post transplant lymphoproliferative disorder 29.20 20.76 18 10011 15595 110563675
Drug hypersensitivity 29.19 20.76 99 9930 453991 110125279
Total lung capacity abnormal 28.78 20.76 12 10017 4571 110574699
Cardiac disorder 28.70 20.76 35 9994 76245 110503025
Rash erythematous 28.31 20.76 36 9993 81796 110497474
Pulmonary vasculitis 27.70 20.76 13 10016 6547 110572723
Influenza like illness 27.64 20.76 37 9992 88375 110490895
Dysarthria 27.53 20.76 36 9993 84085 110495185
Drug interaction 27.30 20.76 6 10023 500177 110079093
Meningomyelitis herpes 26.93 20.76 5 10024 88 110579182
Spirometry abnormal 26.68 20.76 12 10017 5485 110573785
Pyrexia 26.45 20.76 155 9874 898110 109681160
Oesophageal disorder 26.10 20.76 10 10019 3060 110576210
Bursitis 25.81 20.76 44 9985 129874 110449396
Toxicity to various agents 25.75 20.76 6 10023 480549 110098721
Immobile 25.72 20.76 13 10016 7689 110571581
Appetite disorder 25.54 20.76 14 10015 9755 110569515
Osteoporosis 25.02 20.76 35 9994 87117 110492153
Sleep disorder due to a general medical condition 24.81 20.76 27 10002 52085 110527185
Depressive symptom 24.63 20.76 13 10016 8401 110570869
Respiratory tract infection 23.98 20.76 31 9998 71586 110507684
Diarrhoea 23.71 20.76 42 9987 1139463 109439807
Anaemia 23.68 20.76 10 10019 547076 110032194
Palpitations 22.96 20.76 47 9982 159165 110420105
Death 22.82 20.76 18 10011 698851 109880419
Dolichocolon 22.75 20.76 4 10025 51 110579219
Hypotension 21.99 20.76 10 10019 523839 110055431
Pneumocystis jirovecii pneumonia 21.85 20.76 23 10006 42712 110536558
Steroid dependence 21.76 20.76 12 10017 8457 110570813
Condition aggravated 21.72 20.76 127 9902 734709 109844561
Dizziness 21.55 20.76 19 10010 698174 109881096
Strongyloidiasis 21.42 20.76 10 10019 4976 110574294

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
FDA MoA N0000175450 Corticosteroid Hormone Receptor Agonists
FDA EPC N0000175576 Corticosteroid
MeSH PA D005938 Glucocorticoids
MeSH PA D006728 Hormones
MeSH PA D000893 Anti-Inflammatory Agents
MeSH PA D000970 Antineoplastic Agents
MeSH PA D018931 Antineoplastic Agents, Hormonal
CHEBI has role CHEBI:22587 antiviral agent
CHEBI has role CHEBI:33231 antitubercular agent
CHEBI has role CHEBI:33281 antimicrobial agent
CHEBI has role CHEBI:35441 antiinfective agent
CHEBI has role CHEBI:35472 anti-inflammatory drug
CHEBI has role CHEBI:35476 antipsychotic agent
CHEBI has role CHEBI:35526 hypoglycemic agent
CHEBI has role CHEBI:35610 antineoplastic agent
CHEBI has role CHEBI:35674 antihypertensive agent
CHEBI has role CHEBI:35703 xenobiotic
CHEBI has role CHEBI:35705 immunosuppressive agent
CHEBI has role CHEBI:35816 leprostatic drug
CHEBI has role CHEBI:35842 antirheumatic drug
CHEBI has role CHEBI:37962 adrenergic agent
CHEBI has role CHEBI:39456 antiglaucoma drug
CHEBI has role CHEBI:49103 drug metabolite
CHEBI has role CHEBI:49201 anti-ulcer drug
CHEBI has role CHEBI:50177 dermatologic drug
CHEBI has role CHEBI:50671 antithyroid drug
CHEBI has role CHEBI:50748 antipsoriatic
CHEBI has role CHEBI:53784 antispasmodic drug
CHEBI has role CHEBI:64946 anti-HIV agent
CHEBI has role CHEBI:65023 anti-asthmatic agent
CHEBI has role CHEBI:66981 ophthalmology drug
CHEBI has role CHEBI:67079 anti-inflammatory agent
CHEBI has role CHEBI:75835 anti-anaemic agent
CHEBI has role CHEBI:76595 nephroprotective agent
CHEBI has role CHEBI:77715 nasal decongestant
CHEBI has role CHEBI:78298 environmental contaminant
CHEBI has role CHEBI:231911 renoprotective agent
CHEBI has role CHEBI:233423 antifibrotic agent
CHEBI has role CHEBI:50266 prodrug
CHEBI has role CHEBI:50857 anti-allergic agent
CHEBI has role CHEBI:63562 glucocorticoid receptor agonist

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Blepharoconjunctivitis indication 68659002 DOID:2456
Iridocyclitis indication 77971008
Bacterial conjunctivitis indication 128350005 DOID:9700
Uveitis indication 128473001 DOID:13141
Infective blepharitis indication 312219000
Superficial Ocular Infection indication
Ocular hypertension contraindication 4210003 DOID:9282
Herpes simplex keratitis contraindication 9389005
Herpes simplex dendritic keratitis contraindication 29943008
Fungal infection of eye contraindication 31194008
Severe myopia contraindication 34187009
Tuberculosis of eye contraindication 49107007
Diabetes mellitus contraindication 73211009 DOID:9351
Open-angle glaucoma contraindication 84494001 DOID:1067
Krukenberg spindle contraindication 85430004
Anemia due to enzyme deficiency contraindication 111577008
Deficiency of glucose-6-phosphate dehydrogenase contraindication 124134002 DOID:2862
Eye infection contraindication 128351009
Bacterial infection of eye contraindication 128984004
Viral eye infection contraindication 312132001
Vaccinia keratitis contraindication 397552005
Porphyria contraindication 418470004




🐶 Veterinary Drug Use

SpeciesUseRelation
Cats Superficial ocular inflammations or infections limited to the conjunctiva or the anterior segment of the eye, such as those associated with allergic reactions or gross irritants Indication
Dogs Superficial ocular inflammations or infections limited to the conjunctiva or the anterior segment of the eye, such as those associated with allergic reactions or gross irritants Indication
Dogs Treatment when a rapid adrenal glucocorticoid and/or anti-inflammatory effect is necessary Indication

🐶 Veterinary products

ProductApplicantIngredients
Hydeltrone Ointment Boehringer lngelheim Animal Health USA Inc. 2
Prednis-A-Vet Injection Bimeda Animal Health Limited 1

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 1.75 acidic
pKa2 6.8 acidic
pKa3 12.78 acidic
pKa4 13.76 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Glucocorticoid receptor Nuclear hormone receptor AGONIST DRUG LABEL DRUG LABEL

External reference:

IDSource
D00981 KEGG_DRUG
4017987 VUID
N0000146333 NUI
4017987 VANDF
4017988 VANDF
CHEBI:8379 CHEBI
TUA PDB_CHEM_ID
CHEMBL1201014 ChEMBL_ID
C009022 MESH_SUPPLEMENTAL_RECORD_UI
IV021NXA9J UNII
441409 PUBCHEM_CID
DB14631 DRUGBANK_ID
34374 RXNORM
16516 MMSL
37825 MMSL
44390 MMSL
5347 MMSL
5349 MMSL
59710 MMSL
d00084 MMSL
002155 NDDF
002157 NDDF
116601002 SNOMEDCT_US
52388000 SNOMEDCT_US
96335004 SNOMEDCT_US
C0138273 UMLSCUI
C0032950 UMLSCUI
CHEMBL1201231 ChEMBL_ID
DB00860 DRUGBANK_ID
5755 PUBCHEM_CID
535 INN_ID
D011239 MESH_DESCRIPTOR_UI
CHEBI:8378 CHEBI
IV021NXA9J INXIGHT DRUGS

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Prednisolone Sodium Phosphate HUMAN PRESCRIPTION DRUG LABEL 1 0121-0759 SOLUTION 15 mg ORAL ANDA 19 sections
Prednisolone Sodium Phosphate HUMAN PRESCRIPTION DRUG LABEL 1 0121-0773 SOLUTION 10 mg ORAL ANDA 20 sections
Prednisolone Sodium Phosphate HUMAN PRESCRIPTION DRUG LABEL 1 0121-0777 SOLUTION 20 mg ORAL ANDA 20 sections
PrednisoLONE Sodium Phosphate HUMAN PRESCRIPTION DRUG LABEL 1 0121-1100 SOLUTION 5 mg ORAL NDA 17 sections
Prednisolone Sodium Phosphate HUMAN PRESCRIPTION DRUG LABEL 1 0121-4759 SOLUTION 15 mg ORAL ANDA 19 sections
Prednisolone Sodium Phosphate HUMAN PRESCRIPTION DRUG LABEL 1 11695-1431 SOLUTION/ DROPS 10 mg OPHTHALMIC ANDA 14 sections
Prednisolone Sodium Phosphate HUMAN PRESCRIPTION DRUG LABEL 1 13925-166 SOLUTION 5 mg ORAL NDA 17 sections
Prednisolone Sodium Phosphate HUMAN PRESCRIPTION DRUG LABEL 1 17856-0759 SOLUTION 15 mg ORAL ANDA 19 sections
Prednisolone Sodium Phosphate HUMAN PRESCRIPTION DRUG LABEL 1 17856-0815 SOLUTION 15 mg ORAL ANDA 17 sections
Prednisolone Sodium Phosphate HUMAN PRESCRIPTION DRUG LABEL 1 17856-8815 SOLUTION 15 mg ORAL ANDA 17 sections
Sulfacetamide Sodium and Prednisolone Sodium Phosphate HUMAN PRESCRIPTION DRUG LABEL 2 21695-186 SOLUTION 2.50 mg OPHTHALMIC ANDA 18 sections
Sulfacetamide Sodium and Prednisolone Sodium Phosphate HUMAN PRESCRIPTION DRUG LABEL 2 24208-317 SOLUTION/ DROPS 2.30 mg OPHTHALMIC ANDA 20 sections
PREDNISOLONE SODIUM PHOSPHATE HUMAN PRESCRIPTION DRUG LABEL 1 24208-715 SOLUTION/ DROPS 10 mg OPHTHALMIC ANDA 15 sections
Prednisolone Sodium Phosphate HUMAN PRESCRIPTION DRUG LABEL 1 42254-102 SOLUTION 15 mg ORAL ANDA 11 sections
Prednisolone Sodium Phosphate HUMAN PRESCRIPTION DRUG LABEL 1 42799-812 SOLUTION 10 mg ORAL ANDA 17 sections
Prednisolone Sodium Phosphate HUMAN PRESCRIPTION DRUG LABEL 1 42799-813 SOLUTION 20 mg ORAL ANDA 17 sections
Prednisolone Sodium Phosphate HUMAN PRESCRIPTION DRUG LABEL 1 42799-815 SOLUTION 15 mg ORAL ANDA 17 sections
Prednisolone Sodium Phosphate HUMAN PRESCRIPTION DRUG LABEL 1 42799-816 SOLUTION 25 mg ORAL ANDA 17 sections
Prednisolone Sodium Phosphate Oral Solution HUMAN PRESCRIPTION DRUG LABEL 1 44523-182 SOLUTION 25 mg ORAL ANDA 15 sections
Prednisolone Sodium Phosphate Oral Solution HUMAN PRESCRIPTION DRUG LABEL 1 44523-182 SOLUTION 25 mg ORAL ANDA 15 sections
Prednisolone Sodium Phosphate HUMAN PRESCRIPTION DRUG LABEL 1 50090-0955 SOLUTION 15 mg ORAL ANDA 10 sections
Prednisolone Sodium Phosphate HUMAN PRESCRIPTION DRUG LABEL 1 50090-1582 SOLUTION 15 mg ORAL ANDA 19 sections
Prednisolone Sodium Phosphate HUMAN PRESCRIPTION DRUG LABEL 1 50436-0759 SOLUTION 15 mg ORAL ANDA 19 sections
prednisolone sodium phosphateODT Human Prescription Drug Label 1 50742-383 TABLET, ORALLY DISINTEGRATING 10 mg ORAL NDA AUTHORIZED GENERIC 24 sections
prednisolone sodium phosphateODT Human Prescription Drug Label 1 50742-384 TABLET, ORALLY DISINTEGRATING 15 mg ORAL NDA AUTHORIZED GENERIC 24 sections
prednisolone sodium phosphateODT Human Prescription Drug Label 1 50742-385 TABLET, ORALLY DISINTEGRATING 30 mg ORAL NDA AUTHORIZED GENERIC 24 sections
Sulfacetamide Sodium and Prednisolone Sodium Phosphate HUMAN PRESCRIPTION DRUG LABEL 2 53002-8690 SOLUTION/ DROPS 2.30 mg OPHTHALMIC ANDA 19 sections
Prednisolone Sodium Phosphate HUMAN PRESCRIPTION DRUG LABEL 1 54868-5242 SOLUTION 15 mg ORAL ANDA 11 sections
OrapredODT Human Prescription Drug Label 1 59212-700 TABLET, ORALLY DISINTEGRATING 10 mg ORAL NDA 25 sections
OrapredODT Human Prescription Drug Label 1 59212-701 TABLET, ORALLY DISINTEGRATING 15 mg ORAL NDA 25 sections